Clinical Trial Solutions

Applied Genetics Technology Company (AGTC) partners with 20/20 for their nationwide ophthalmic phase 1 and 2 clinical trials

READ CASE STUDY

Observational Study Confirms Eye Exams in Mobile Settings Have the Same Results as In-Office Exams

Keeping Your Trials on Track: How Mobile Vision Clinics Are Making an Impact on Pre-screening, Screening and Retention

READ WHITEPAPER

Meet 20/20 Onsite's Industry and Scientific Advisory Board

The Industry and Scientific Advisory Board (IASAB) meets quarterly to help identify patient needs, product opportunities, and market challenges associated with the provision of vision-related assessments for clinical trials and safety surveillance.

Rajat Agrawal, MD, MS

CEO and President Retina Global

Jeanne Hecht, Chair

Founder and CEO JTH Consulting, LLC

Jeffrey S. Heier, MD

Director of the Vitreoretinal Service and Director of Retina Research Ophthalmic Consultants of Boston (OCB)

Peter K. Kaiser, MD

Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology Cleveland Clinic Lerner College of Medicine

Beth Marsh

Vice President of North America Sales and Marketing, Ophthalmology Apellis Pharmaceuticals

Jason Menzo

Chief Operating Officer Foundation Fighting Blindness

Adam Ramsey, OD

Owner Socialite Vision

Click below to read more about each board member's commitment to research or submit a question to be asked during our next quarterly meeting.

LEARN MORE ABOUT OUR IASAB AND THEIR VISION FOR INNOVATION

Clinical trials with 20/20 Onsite

Accelerate enrollment, expand reach, and create a frictionless patient experience

With more than 80% of US clinical trials failing to meet their patient enrollment timelines and with an average of 30% of patients dropping out, point-of-need vision clinics are a game changer.

Clinical Trials and Research

Late Phase or Post-marketing

Mobile Vision Clinic

Mobile vision suite

Mobile Vision Pod